5SAKAMOTO Y, MAKUUCHI-M, HARIHARA Y, et al.Correlation between neurotoxic events and intracercbral concentration of tacrolimus in rats [J]. Biol Pharm Bu11,2000,23(8):1008-1010.
1[1]The Mycophenolate Mofetil Renal Refractory Rejection Study Group. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection[J].Transplantation, 1996,61(5):722-729.
2[2]UNDRE NA, STEVENSON P, SCHAFER A. Pharmacokinetics of tacrolimus:clinically relevant aspects[J].Transplant Proc, 1999,31(7):21S-24S.
3[3]VENKATARAMANAN R, JAIN A, WARTY VS, et al. Pharmacokinetics of FK506 in transplant patients[J].Transplant Proc, 1991,23(6):2736-2740.
4[4]MIHATSCH MJ, KYO M, MOROZUMI K, et al. The side-effects of ciclosporine-A and tacrolimus[J].Clin Nephrol, 1998,49(6):356-363.
5[1]Plosker GL, Foster RH. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation[J].Drugs, 2000,59(2) :323.
6[2]Backman L, Nicar M. FK506 trough levels in whole blood and plasma in liver transplant recipients[J]. Transplantation, 1994,57(4) :519.
7[3]Bottiger Y, Brattstrom C, Tyden G, et al. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients.Br J Clin Pharmacol, 1999,48(3) :445.
8[4]Cadoff EM, Venkataramanan R, Krajack A, et al. Assay of FK 506 in plasma[J]. Transplant Proc, 1990,22(1):50.
9[5]Brunet M, Pou L, Torra M, et al. Comparative analysis of tacrolimus (FK506) in whole blood liver transplant recipients by PRO-TRAC enzyme-linked immunosorbent assay and microparticle enzyme immunoassay IMX methods[J]. Ther Drug Monit, 1996,18(6) :706.
10[6]Jain A, Reyes J. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients[J]. Ann Surg, 1999,230(3) :441.
